ライフサイエンスコーパス: premenopausal women

1 inal approach in eight postmenopausal and 25 premenopausal women.

2 e of the results were significant for men or premenopausal women.

3 ared with breast cancers diagnosed in young, premenopausal women.

4 y cycles and sporadic anovulation in healthy premenopausal women.

5 thdrawal and induced hypogonadism in healthy premenopausal women.

6 a cross-sectional study of fibroids in 1152 premenopausal women.

7 lead to progression of ER+ breast cancer in premenopausal women.

8 ely associated with breast cancer risk among premenopausal women.

9 lymorphism is responsible for this effect in premenopausal women.

10 luated patterns among regularly menstruating premenopausal women.

11 f anti-estrogen therapies to treat cancer in premenopausal women.

12 tor to disease severity in children, men, or premenopausal women.

13 r risk of second breast neoplastic events in premenopausal women.

14 reast cancer in postmenopausal and high-risk premenopausal women.

15 term habituation in 16 obese and 16 nonobese premenopausal women.

16 us (LBSQ) fat were measured in 28 men and 53 premenopausal women.

17 sterol levels independent of estradiol among premenopausal women.

18 gher dietary requirement for choline than do premenopausal women.

19 and to correlate amenorrhea with outcomes in premenopausal women.

20 associated with lower LPO concentrations in premenopausal women.

21 ociation between fiber and cholesterol among premenopausal women.

22 e does not have an adverse effect on bone in premenopausal women.

23 lude ovulation, has not been well studied in premenopausal women.

24 r for reducing risk of early menopause among premenopausal women.

25 cations; long-term effects; and nonwhite and premenopausal women.

26 ual syndrome (PMS) affects as many as 20% of premenopausal women.

27 n and those of the Native Mexican diet among premenopausal women.

28 e consistent among postmenopausal than among premenopausal women.

29 ominal fat increases in overweight and obese premenopausal women.

30 and lower body subcutaneous fat depots in 21 premenopausal women.

31 /obese (body mass index, 27-40) nondiabetic, premenopausal women.

32 but this has not been examined in overweight premenopausal women.

33 ary syndrome is estimated to affect 5-10% of premenopausal women.

34 evated SBP and PP are potent risk factors in premenopausal women.

35 y prohepcidin and iron absorption in healthy premenopausal women.

36 2 microg/L), as commonly observed in healthy premenopausal women.

37 east and ovarian cancers, particularly among premenopausal women.

38 ed with ovarian cancer risk, particularly in premenopausal women.

39 linically detected uterine leiomyomata among premenopausal women.

40 ipheral blood mononuclear cells from healthy premenopausal women.

41 Relationships were strongest among premenopausal women.

42 loxifene for breast cancer risk reduction to premenopausal women.

43 strogen therapies, particularly tamoxifen in premenopausal women.

44 nd patient prognosis, most prominently among premenopausal women.

45 EXT, alongside data from the cohort of older premenopausal women.

46 noteworthy associations were observed among premenopausal women.

47 level of symptom burden was similar in older premenopausal women.

48 t but are not worse than those seen in older premenopausal women.

49 targeted biologic therapy, and treatment of premenopausal women.

50 .19 +/- 0.11 vs 0.30 +/- 0.12; P < .05) than premenopausal women.

51 improved menstrual cycle function in healthy premenopausal women.

52 factors have been identified, especially for premenopausal women.

53 uppression or ablation should be included in premenopausal women.

54 xhibited a pattern of brain activity akin to premenopausal women.

55 eased risk of hepatic fibrosis compared with premenopausal women.

56 Among 2027 premenopausal women (13.1%), biennial screeners had high

57 Fifty-seven adult subjects (26 men, 16 premenopausal women, 15 postmenopausal women) were fed a

58 (interquartile range, 21.8%; n = 230) among premenopausal women, 31.0% (interquartile range, 23.2%;

59 associated with the menstrual status (BEC in premenopausal women, 31.48 +/- 20.68 [standard deviation

60 ne-related organ dysfunction was observed in premenopausal women: 80%, 43%, and 13% of women with 2,

61 mammograms linked to 1283 breast cancers in premenopausal women according to week of menstrual cycle

62 nopausal women age 65 or older compared with premenopausal women age 45 or younger (P = .005); simila

63 fected men aged 40-49 years and HIV-infected premenopausal women aged >/=40 years.

64 A total of 166 premenopausal women aged < or = 50 years were recruited

65 Premenopausal women aged 35-55 years were followed from

66 s before GB) than men, 51 healthy adults, 22 premenopausal women (aged 28+/-1 years, mean+/-SE) and 2

67 Participants were 72 healthy premenopausal women, ages 19-52 years, with no current o

68 In this paper I propose that, in premenopausal women, an iron deficiency caused by menstr

69 actors was 52.7% (95% CI, 49.1%-56.3%) among premenopausal women and 54.7% (95% CI, 46.5%-54.7%) amon

70 the mean (SD) age was 46.3 (3.7) years among premenopausal women and 61.7 (7.2) years among the postm

71 iuria is present in an estimated 1% to 6% of premenopausal women and an estimated 2% to 10% of pregna

72 intake and reproductive hormones in healthy premenopausal women and evaluated the potential effect m

73 age, was lower in postmenopausal compared to premenopausal women and in smokers compared to non-smoke

74 on of arterial blood pressure (BP) differ in premenopausal women and men of similar age.

75 and earlier start and end to childbearing in premenopausal women and obesity in postmenopausal women

76 o levels observed during the luteal phase of premenopausal women and were significantly (P=0.0389) lo

77 with the number of alleles of rs12325817 in premenopausal women and whether postmenopausal women (wi

78 cancer, and disproportionally affects young premenopausal women and women of African descent.

79 ll sample, but associations were found among premenopausal women and women who consistently took horm

80 sed, cross-sectional study of 7137 men, 4585 premenopausal women, and 2248 postmenopausal women aged

81 elopment of triple-negative breast cancer in premenopausal women, and altered gene and miRNA expressi

82 s dictates levels of circulating estrogen in premenopausal women, and its aberrant overexpression in

83 ions were 140.7, 49.4, and 96.7 mg/L in men, premenopausal women, and postmenopausal women, respectiv

84 west quartile of percentage fat mass in men, premenopausal women, and postmenopausal women, the adjus

85 spine and femoral neck, stratified by male, premenopausal women, and postmenopausal women.

86 Power was low for premenopausal women, and the associations were not signi

87 n; 27.2%, 17.2%, and 10.6%, respectively, in premenopausal women; and 18.4%, 12.7%, and 10.5%, respec

88 The notion that premenopausal women are more resistant than men to shock

89 Circulating levels of estrogen in premenopausal women are primarily determined by the acti

90 trogen may be one of the mechanisms by which premenopausal women are protected against cardiovascular

91 Premenopausal women are relatively protected from develo

92 Premenopausal women are relatively protected from the di

93 Premenopausal women are relatively resistant to choline

94 in in breast cancer etiology, yet studies in premenopausal women are scarce.

95 es more favorable tumor characteristics when premenopausal women are screened annually vs biennially.

96 wever, data on its physiologic regulation in premenopausal women are sparse.

97 Older studies in premenopausal women argue that the benefit with chemothe

98 nd 1.6 (1.0, 2.5) (P = 0.03) for men, having premenopausal women as a reference.

99 Screening of women ages 40-49 years (or premenopausal women, as determined from patient history,

100 gical outcomes associated with ID and IDA in premenopausal women, as the prevalence of ID and IDA is

101 ed by serum 25-hydroxyvitamin D (25-OHD), in premenopausal women at initiation of adjuvant chemothera

102 n (18)F-FDG uptake was seen predominantly in premenopausal women at mid menstrual cycle.

103 nostic effect on recurrence-free survival in premenopausal women at risk for breast cancer.

104 This mechanism results in premenopausal women being more susceptible to angiogenes

105 Unlike age-matched men, premenopausal women benefit from cardiovascular protecti

106 ated with a reduced risk of breast cancer in premenopausal women but an increased risk in postmenopau

107 ed follicular estradiol concentrations among premenopausal women but does not appear to affect ovulat

108 one-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxif

109 ifen has greater efficacy and can be used in premenopausal women, but raloxifene has fewer side-effec

110 ntaining beverages are widely consumed among premenopausal women, but their association with reproduc

111 for both men and women, occur uncommonly in premenopausal women, but their incidence rises sharply a

112 Many premenopausal women choose to take hormone replacement t

113 Insulin sensitivity is greater in premenopausal women compared with age-matched men, and m

114 ine in renal function in nondiabetic CKD for premenopausal women compared with men.

115 However, only a portion of premenopausal women developed such problems.

116 liver or muscle damage, whereas only 44% of premenopausal women developed such signs of organ dysfun

117 r or muscle damage), while less than half of premenopausal women developed such signs.

118 Premenopausal women diagnosed as having breast cancer fo

119 ggest that identification of hypertension in premenopausal women dictates additional CAD risk factor

120 In this population of Latin American premenopausal women, different fat distributions in adul

121 Overweight premenopausal women do not lose bone during weight loss

122 Premenopausal women exhibit enhanced insulin sensitivity

123 study were largely null, it is possible that premenopausal women exposed to passive smoke or carrying

124 risk factors or outcomes based on studies of premenopausal women followed through the menopause trans

125 ions and breast cancer risk in predominately premenopausal women from the Nurses' Health Study II.

126 from the first Nurses' Health Study and 1114 premenopausal women from the second Nurses' Health Study

127 A total of 259 healthy, premenopausal women from Western New York were followed

128 ies (children 9-13 y old, males >/=14 y old, premenopausal women >/=19 y old, and postmenopausal wome

129 Premenopausal women had a greater risk of breast cancer

130 Twenty percent of premenopausal women had angiographic CAD versus 31% of p

131 Premenopausal women had lower mean (standard deviation)

132 Premenopausal women had significantly higher BEC when co

133 These results may help explain why premenopausal women have lower incidence of T2D than age

134 Premenopausal women have lower tonic sympathoadrenal act

135 For premenopausal women, higher intake of folate was associa

136 oductive hormones and oxidative stress among premenopausal women, however, has yet to be clearly eluc

137 n and breast cancer risk among predominately premenopausal women; however, further follow-up is neede

138 The association was restricted to premenopausal women (HR = 1.40, ptrend = 0.01), even aft

139 .38; 95% CI, 0.98-5.76, N cases = 50) and in premenopausal women (HR = 3.42; 95% CI, 1.08-10.85).

140 gen metabolites and breast cancer risk among premenopausal women in a case-control study nested withi

141 ociated with breast cancer risk reduction in premenopausal women in the Mayo Clinic study, with allel

142 e intake and breast cancer risk among 90,628 premenopausal women in the Nurses' Health Study II.

143 metric, lifestyle, and dietary factors among premenopausal women in the United States.

144 s that endogenous hormones affect density in premenopausal women; in particular, it shows a positive

145 al FA, and direct free FA (FFA) storage than premenopausal women, including two-fold greater meal FA

146 In premenopausal women, increased number of ESR1 PvuII and

147 Conversely, in premenopausal women, increased risks were associated wit

148 significantly lower risk of breast cancer in premenopausal women (IRR: 0.70; 95% CI: 0.52, 0.96; P fo

149 However, a significant subset of premenopausal women is protected from CDS.

150 ing the Mediterranean diet with lower LPO in premenopausal women is sparse.

151 This cross-sectional study of 494 premenopausal women is the first to account for cyclic v

152 ein intakes for optimizing bone health among premenopausal women is unclear.

153 ER(+) cell frequencies, respectively, among premenopausal women (Ki67(hi)/p27(lo): OR = 5.08, 95% CI

154 In eight premenopausal women, LBNP decreased muscle oxygenation b

155 s a particularly high false-positive rate in premenopausal women, leading to unnecessary surgical int

156 Fifty premenopausal women living with HIV in Kampala, Uganda,

157 this study was to assess whether overweight premenopausal women lose bone with moderate weight loss

158 included 98 previously sexually functioning, premenopausal women (mean [SD] age 37.1 [6] years) whose

159 ge at menopause (age at blood collection for premenopausal women) minus age at menarche, subtracting

160 ge at menopause (age at blood collection for premenopausal women) minus age at menarche, years of ora

161 st association with fat mass was observed in premenopausal women (n = 1192; P = .02).

162 Premenopausal women (n = 27) consumed a choline-sufficie

163 Overweight premenopausal women [n = 44; x (+/-SD) age: 38 +/- 6.4 y

164 r age at last use, and more recent use among premenopausal women; no significant associations were fo

165 breast cancer risk were null, whereas among premenopausal women, nonsignificant positive association

166 Among regularly screened premenopausal women, obesity was not associated with inc

167 ciated with triple-negative breast cancer in premenopausal women (odds ratio 2.307, 95% CI 1.261-4.21

168 ith regular use of NSAIDs was stronger among premenopausal women (odds ratio = 0.62).

169 ce interval: 1.24, 2.57), particularly among premenopausal women (odds ratio = 2.49) but not among po

170 examined the effect in healthy, overweight, premenopausal women of a diet and exercise weight-loss p

171 rkable finding was the strong association in premenopausal women of the 5,10-methylenetetrahydrofolat

172 Associations were similar among premenopausal women only.

173 xcess risk was observed for breast cancer in premenopausal women or for thyroid cancer.

174 n for the primary prevention of fractures in premenopausal women or in men.

175 may be associated with breast cancer risk in premenopausal women or women <50 y.

176 The association was significantly greater in premenopausal women (OR = 1.69; 95% CI: 1.17, 2.43) than

177 al/Val genotype was seen predominantly among premenopausal women (OR = 2.08; 95% CI = 1.20, 3.59).

178 sal women (OR, 0.6; 95% CI, 0.4-0.8) than in premenopausal women (OR, 0.8; 95% CI, 0.6-1.1).

179 This association was more pronounced among premenopausal women (OR, 2.1; 95% CI, 0.8-5.5) than post

180 ely associated with breast cancer risk among premenopausal women [OR = 10.1, 95% confidence interval

181 Premenopausal women overestimate PA estimates on questio

182 was positively associated with CRP levels in premenopausal women (P < 0.0001).

183 adratic relationship between Hct and LVMI in premenopausal women (p < 0.01).

184 = 0.04), lower current body mass index among premenopausal women (P heterogeneity = 0.01), and older

185 factor, higher current body mass index among premenopausal women (P heterogeneity = 0.03).

186 nly OC duration was positively associated in premenopausal women (p<0.0001).

187 compared with 12.8% of vegetarians in white premenopausal women; P < 0.05 after Bonferroni correctio

188 ibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects

189 ologic (18)F-FDG uptake in normal ovaries of premenopausal women poses another limitation.

190 Postmenopausal women, or premenopausal women receiving a gonadotropin-releasing h

191 Premenopausal women receiving chemotherapy for BC sustai

192 r zoledronic acid (ZA) prevents bone loss in premenopausal women receiving chemotherapy for early-sta

193 In premenopausal women receiving letrozole for neoadjuvant

194 ealth and well-being of approximately 25% of premenopausal women, risk factors are poorly understood.

195 Among premenopausal women, risk was increased for ever use of

196 Along this line, premenopausal women seem to be generally protected from

197 Evidence suggests that in premenopausal women, sex hormones, particularly estrogen

198 Premenopausal women should be advised of the potential e

199 with screening of women ages 40-49 years (or premenopausal women starting at age 40 years) making a n

200 We randomly assigned 3066 premenopausal women, stratified according to prior recei

201 remenstrual syndrome (PMS) affects 15-20% of premenopausal women, substantially reducing quality of l

202 serial breast biopsy analysis in nonpregnant premenopausal women suggested relatively stable baseline

203 In premenopausal women, tamoxifen for 5 years reduces the r

204 Among premenopausal women, TCDD serum levels were associated w

205 (pmol PtdCho-DHA/nmol PtdCho) was higher in premenopausal women than in men and postmenopausal women

206 prevalence of ID and IDA is often greater in premenopausal women than other population demographics.

207 Among premenopausal women, the association with OS was stronge

208 Among premenopausal women, the effect of bariatric surgery was

209 Among premenopausal women, the radicalPD difference per 10-yea

210 east cancer recurrence overall, although for premenopausal women there was a significant inverse asso

211 For simple cysts in premenopausal women, these thresholds are 3 cm for repor

212 were prospectively evaluated in asymptomatic premenopausal women to determine whether the onset of de

213 duces expression of the PEMT gene and allows premenopausal women to make more of their needed choline

214 bitors (combined with ovarian suppression in premenopausal women) to prevent bone fractures has not b

215 Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for

216 Premenopausal women undergoing chemotherapy for breast c

217 ne whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast c

218 Premenopausal women undergoing commonly used genotoxic (

219 effect on ovarian function and fertility in premenopausal women undergoing treatment for early-stage

220 a in preventing early ovarian dysfunction in premenopausal women undergoing treatment for EBC were se

221 Premenopausal women underwent serial BMD measurements be

222 celerated IMT progression (0.003 mm/year for premenopausal women vs. 0.008 mm/year for perimenopausal

223 ference in percent MD (PD) between post- and premenopausal women was apparent (-0.46 cm [95% CI: -0.5

224 l dysphoric disorder, which affects 2%-5% of premenopausal women, was included in Appendix B of DSMIV

225 as groups receiving blood transfusions, the premenopausal women were also found to have lower initia

226 Twelve healthy Caucasian premenopausal women were compared to a group of healthy

227 In all, 345 premenopausal women were enrolled: 171 on tamoxifen alon

228 Healthy premenopausal women were followed for </=2 menstrual cyc

229 Over an 8-y period (2001-2009), 12,044 premenopausal women were followed for a first diagnosis

230 From 1997 to 2009, 23,580 premenopausal women were followed for incident uterine l

231 A total of 60 healthy, overweight, premenopausal women were included in a 6-mo weight-loss

232 were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen

233 Twelve normal premenopausal women were scanned twice during the early

234 nd EA regions between the postmenopausal and premenopausal women were significantly different (p = 0.

235 /dL) for early postmenopausal, compared with premenopausal, women were 2.1 (95% confidence interval:

236 Postmenopausal women, compared with premenopausal women, were at increased risk (incidence r

237 contribute to the lower chronic BP levels of premenopausal women, whereas attenuated BRB of BP may he

238 Renal involvement was more common in premenopausal women, whereas vascular arterial events we

239 ic tachycardia syndrome (POTS) are primarily premenopausal women, which may be attributed to female s

240 dered standard of care for risk reduction in premenopausal women who are at least 35 years old and ha

241 recurrence score, could be used to identify premenopausal women who could benefit from more effectiv

242 After 4 months of tamoxifen, premenopausal women who did not receive adjuvant chemoth

243 Premenopausal women who first gave birth before age 20 y

244 OR], 4.16; 95% CI, 1.29-13.45; P = .02), and premenopausal women who gave birth to their last child b

245 From December 2008 to August 2011, 58 premenopausal women who had undergone contrast material-

246 Conclusion: Premenopausal women who undergo regular screening may be

247 y was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger.

248 Cases were predominantly premenopausal women who were diagnosed with incident bre

249 We included premenopausal women who were diagnosed with invasive bre

250 ultures of voided midstream urine in healthy premenopausal women with acute uncomplicated cystitis ac

251 Forty premenopausal women with AN and 40 normal-weight women o

252 Premenopausal women with axillary lymph node-positive, s

253 Premenopausal women with axillary node-negative, hormone

254 Fifty-five men and 85 premenopausal women with BMI 18-24 (lean) and 27-36 kg/m

255 Premenopausal women with breast cancer receiving adjuvan

256 Premenopausal women with breast cancer, and specifically

257 eparation for adjuvant chemotherapy in young premenopausal women with breast cancer.

258 We obtained data for 11 906 premenopausal women with early breast cancer randomised

259 Thirty-four young premenopausal women with early-stage breast cancer who w

260 Ovarian preservation in premenopausal women with early-stage endometrial cancer

261 nt Ovarian Ablation (OA) in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Can

262 Among premenopausal women with either hormone receptor-positiv

263 Oophorectomy is commonly performed in premenopausal women with endometrial cancer who undergo

264 We studied premenopausal women with epilepsy receiving antiepilepti

265 all genotyped individuals, eight (33%) of 24 premenopausal women with ER/PR-negative cancer had the K

266 Premenopausal women with estrogen and/or progesterone re

267 nists is an effective adjuvant treatment for premenopausal women with estrogen receptor (ER) -positiv

268 east cancer risk in postmenopausal women and premenopausal women with genetic or familial risk factor

269 on Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive

270 nvestigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breas

271 ntial antitumor activity in the treatment of premenopausal women with hormone receptor-positive metas

272 Premenopausal women with hormone receptor-positive, HER2

273 Between Nov 7, 2003, and April 7, 2011, 4717 premenopausal women with hormone-receptor positive breas

274 additional class of agents for treatment of premenopausal women with hormone-receptor-positive breas

275 In premenopausal women with hormone-receptor-positive early

276 In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early

277 ation both independently improve survival in premenopausal women with hormone-sensitive breast cancer

278 Premenopausal women with HR-positive/HER2-negative breas

279 ualize endocrine therapy decision making for premenopausal women with human epidermal growth factor r

280 ns in 1996-1999 and 2007, we ascertained 310 premenopausal women with incident endometriosis and 615

281 ough March 2001, the authors followed 22,895 premenopausal women with intact uteri and no prior self-

282 r than previous studies and included 102,164 premenopausal women with intact uteri, no prior history

283 ent normal and breast cancer tissues from 96 premenopausal women with known clinical reproductive his

284 s of breast cancer are diagnosed annually in premenopausal women with limited economic resources.

285 In this population of healthy premenopausal women with low exposure levels, cadmium, l

286 Premenopausal women with no lifetime history of major de

287 In premenopausal women with operable breast cancer not sele

288 From 1993 to 1999, we recruited 709 premenopausal women with operable breast cancer to a mul

289 We randomly assigned 257 premenopausal women with operable hormone-receptor-negat

290 All but premenopausal women with receptor negative tumors receiv

291 Coronary flow velocity in 18 premenopausal women with SLE (mean +/- SD age 29.4 +/- 5

292 re coronary flow reserve (CFR) in a group of premenopausal women with SLE and a group of age-, sex-,

293 Premenopausal women with stage cT2 to 4b, any N, M0; est

294 Between October 2003 and January 2008, 281 premenopausal women with stage I to III hormone receptor

295 of oral contraceptives on lupus activity in premenopausal women with systemic lupus erythematosus.

296 This ratio was lower in premenopausal women with the rs12325817 polymorphism in

297 ith advanced-stage tumors, and the lowest in premenopausal women with triple-negative cancer.

298 hysterectomy specimens from normally cycling premenopausal women with uterine fibroids, who were not

299 prospective cohort study of 18 555 married, premenopausal women without a history of infertility who

300 in the plasma, erythrocytes, and urine of 30 premenopausal women (x +/- SD age: 41.9 +/- 4.8 y) and 3